KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Investing Activities (2016 - 2025)

CRISPR Therapeutics AG's Cash from Investing Activities history spans 11 years, with the latest figure at $37.2 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 64.85% year-over-year to $37.2 million; the TTM value through Dec 2025 reached -$31.8 million, up 88.66%, while the annual FY2025 figure was -$31.8 million, 88.66% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $37.2 million at CRISPR Therapeutics AG, up from -$119.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $216.9 million in Q2 2023 and bottomed at -$565.2 million in Q3 2021.
  • The 5-year median for Cash from Investing Activities is -$68.8 million (2022), against an average of -$61.6 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 8045.24% in 2021 before it surged 486.87% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$8.7 million in 2021, then plummeted by 1913.91% to -$175.5 million in 2022, then surged by 53.6% to -$81.5 million in 2023, then soared by 229.93% to $105.8 million in 2024, then plummeted by 64.85% to $37.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Cash from Investing Activities are $37.2 million (Q4 2025), -$119.2 million (Q3 2025), and $70.0 million (Q2 2025).